Found: 22
Select item for more details and to access through your institution.
The vast majority of gastric T cells are polarized to produce T helper 1 type cytokines upon antigenic stimulation despite the absence of Helicobacter pylori infection.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma.
- Published in:
- Internal Medicine, 2023, v. 62, n. 12, p. 1775, doi. 10.2169/internalmedicine.0860-22
- By:
- Publication type:
- Article
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
- Published in:
- touchREVIEWS in Endocrinology, 2022, v. 18, n. 1, p. 10, doi. 10.17925/ee.2022.18.1.10
- By:
- Publication type:
- Article
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2694, doi. 10.1111/dom.13859
- By:
- Publication type:
- Article
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2694, doi. 10.1111/dom.13859
- By:
- Publication type:
- Article
Cover Image, Volume 20, Issue 2.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. i, doi. 10.1111/dom.13195
- By:
- Publication type:
- Article
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 378, doi. 10.1111/dom.13082
- By:
- Publication type:
- Article
Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 9, p. 1610, doi. 10.1111/jdi.13525
- By:
- Publication type:
- Article
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial.
- Published in:
- Journal of Diabetes Investigation, 2018, v. 9, n. 4, p. 840, doi. 10.1111/jdi.12793
- By:
- Publication type:
- Article
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 4, p. 565, doi. 10.1111/jdi.12457
- By:
- Publication type:
- Article
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallelgroup trial.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 1, p. 76, doi. 10.1111/jdi.12367
- By:
- Publication type:
- Article
Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial 在既往使用胰岛素治疗血糖未得到控制的日本2型糖尿病受试者中比较德谷胰岛素/门冬胰岛素与每日2次双相门冬胰岛素30:泛亚达标治疗3期试验亚组分析
- Published in:
- Journal of Diabetes, 2017, v. 9, n. 3, p. 243, doi. 10.1111/1753-0407.12407
- By:
- Publication type:
- Article
Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
- Published in:
- Diabetology & Metabolic Syndrome, 2016, v. 8, p. 1, doi. 10.1186/s13098-016-0131-y
- By:
- Publication type:
- Article
Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
- Published in:
- Endocrine Journal, 2017, v. 64, n. 12, p. 1165, doi. 10.1507/endocrj.ej17-0189
- By:
- Publication type:
- Article
GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
- Published in:
- European Surgical Research, 2018, v. 59, n. 5/6, p. 349, doi. 10.1159/000494768
- By:
- Publication type:
- Article
Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
- Published in:
- Advances in Therapy, 2021, v. 38, n. 3, p. 1514, doi. 10.1007/s12325-021-01631-y
- By:
- Publication type:
- Article
A Japanese Study Assessing Glycemic Control with Use of IDegAsp Co-formulation in Patients with Type 2 Diabetes in Clinical Practice: The JAGUAR Study.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 3, p. 1638, doi. 10.1007/s12325-021-01623-y
- By:
- Publication type:
- Article
Dipeptidyl‐peptidase 4 inhibitor increased and maintained platelet count in a patient with primary myelofibrosis.
- Published in:
- EJHaem, 2021, v. 2, n. 3, p. 551, doi. 10.1002/jha2.229
- By:
- Publication type:
- Article
1090-P: Diabetes in Japanese COVID-19 Patients as the Primary Factor of Accelerated Progression to Severe State.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1090-P
- By:
- Publication type:
- Article
100-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-100-OR
- By:
- Publication type:
- Article
1631-P: Glycaemic Deterioration, a Clue to Occult Cancer.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1631-P
- By:
- Publication type:
- Article
2304-PUB: Liraglutide also Has Favorable Effects on Body Composition without Decrease in Lean Body.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2304-PUB
- By:
- Publication type:
- Article